Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Daratumumab (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms POLLUX
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 25 Jun 2017 Results assessing the efficacy Daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone in relapsed or refractory multiple myeloma patients with standard or high cytogenetic risk status from CASTOR and POLLUX studies, presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results describing Next Generation Sequencing methodology for determining cytogenetic risk status from CASTOR and POLLUX studies, presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Updated safety and efficacy analysis results based on approximately 25 months follow up, presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top